BIIB vs MCK: fair value comparison
Biogen Inc. and McKesson Corporation · Updated 2026-10-19
BIIB currently screens as overvalued while MCK screens as fairly valued. Within Healthcare, MCK currently sits closer to the top of our ranking by discount to fair value. BIIB carries the stronger quality grade.
| BIIB | MCK | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $225.71 | $938.84 |
| 12-month range | $147.86–$235.35 | $725.17–$1,004.84 |
| Rank by discount to fair value | #73 of 108 Healthcare | #68 of 108 Healthcare |
| Quality grade | B | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BIIB fair value analysis · MCK fair value analysis